IP Library Granted Patent US 9,874,574
Granted Patent B2
US 9,874,574 · App. 14/758,710 · Granted Jan 23, 2018

Marker for detecting proliferation and treatment capacities of adipose-derived stem cell cultured in medium containing EGF or BFGF, and use thereof

Inventors: Kyung Sook Chung (Daejeon, KR); Mi Hyung Kim (Seoul, KR)
Assignees: ANTEROGEN CO. LTD.; KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
G01N33/74C12Q1/6883C12Q2600/106C12Q2600/118G01N2333/726G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,874,574
App. No.
14/758,710
Granted
Jan 23, 2018
Kind
B2
Abstract

The present invention relates to: a composition for detecting a marker for detecting the proliferation capacity or treatment capacity of adipose-derived stem cells cultured in a medium containing epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF); and a detection method.

Claims (12)

1. A method for obtaining adipose-derived stem cells having increased therapeutic potential comprising:

separately culturing adipose-derived stem cells in a basal medium and in such basal medium also containing EGF or bFGF;

separately measuring for adipose-derived stem cells cultured in the basal medium and in the basal medium containing EGF or bFGF, the level of mRNA or of protein encoded by (A) the prostaglandin E receptor 2 (PTGER2) gene and (B) at least one gene selected from the group consisting of the genes encoding 1-acylglycerol-3-phosphate O-acyltransferase 9 (AGPAT9), annexin A10 (ANXA10), insulin-like growth factor 2 binding protein 3 (IGF2BP3), integrin alpha 11 (ITGA11), PRKC apoptosis WT1 regulator (PAWR), and secreted frizzled-related protein 2 (SFRP2); and

recovering adipose-derived stem cells cultured in the basal medium containing EGF or bFGF, for which (A) the amount of mRNA or the protein encoded by the PTGER2 gene is higher than the amount of such mRNA or protein measured in adipose-derived stem cells cultured in the basal medium; and (B) either (1) the amount of mRNA or protein encoded by one of the AGPAT9, ANXA10, or IGF2BP3 gene is higher, or (2) the amount of mRNA or protein encoded by one of the ITGA11, PAWR, or SFRP2 gene is lower than the amount of such mRNA or protein measured in adipose-derived stem cells cultured in the basal medium, thereby obtaining adipose-derived stem cells having increased therapeutic potential.

2. The method according to claim 1 , wherein the measurement of the mRNA level is performed by using a pair of primers or a probe which binds specifically to the gene.

3. The method according to claim 1 , wherein the measurement of the protein level of the genes is performed by using an antibody specific to the protein.

4. A method for obtaining adipose-derived stem cells having increased proliferation potential comprising:

separately culturing adipose-derived stem cells in a basal medium and in such basal medium also containing EGF or bFGF;

separately measuring for adipose-derived stem cells cultured in the basal medium and in the basal medium containing EGF or bFGF, the level of mRNA or of protein encoded by (A) the prostaglandin E receptor 2 (PTGER2) gene and (B) at least one gene selected from the group consisting of the genes encoding 1-acylglycerol-3-phosphate O-acyltransferase 9 (AGPAT9), annexin A10 (ANXA10), insulin-like growth factor 2 binding protein 3 (IGF2BP3), integrin alpha 11 (ITGA11), PRKC apoptosis WT1 regulator (PAWR), and secreted frizzled-related protein 2 (SFRP2); and

recovering adipose-derived stem cells cultured in the basal medium containing EGF or bFGF, for which (A) the amount of mRNA or the protein encoded by the PTGER2 gene is higher than the amount of such mRNA or protein measured in adipose-derived stem cells cultured in the basal medium; and (B) either (1) the amount of mRNA or the protein encoded by one of the AGPAT9, ANXA10, or IGF2BP3 gene is higher, or (2) the amount of mRNA or protein encoded by one of the ITGA11, PAWR, or SFRP2 gene is lower than the amount of such mRNA or protein measured in adipose-derived stem cells cultured in the basal medium, thereby obtaining adipose-derived stem cells having increased proliferation potential.

5. The method according to claim 4 , wherein the measurement of the mRNA level of the genes is performed by using a pair of primers or a probe which binds specifically to the gene.

6. The method according to claim 4 , wherein the measurement of the protein level of the genes is performed by using an antibody specific to the protein.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2015
From: KIM, MI HYUNG
To: ANTEROGEN CO. LTD.
Reel/Frame 036493/0963 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2015
From: CHUNG, KYUNG SOOK
To: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Reel/Frame 036493/0992 →
Priority Claims (1)
KR 10-2013-0067365 · Jun 12, 2013 · national
Continuity (1)
Related Publication 20160178648A1 · Jun 23, 2016